Table 2.
Univariate Cox proportional hazard models for overall survival (OS) and progression-free survival (PFS)
| Variables | PFS |
OS |
||
|---|---|---|---|---|
| Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
| Central type (n = 28) | ||||
| Age | 2.67 (1.08–6.38) | 0.034a | 3.19 (1.11–10.49) | 0.031a |
| Gender (M : F) | 1.37 (0.51–4.75) | 0.56 | 4.04 (0.80–73.50) | 0.10 |
| Smoking index | 0.85 (0.36–2.00) | 0.71 | 0.74 (0.27–2.03) | 0.55 |
| ECOG PS | 1.83 (0.42–5.80) | 0.38 | 0.98 (0.053–5.29) | 0.99 |
| Serum LDH | 1.93 (0.83–4.73) | 0.13 | 3.29 (1.15–10.69) | 0.026 |
| Tumour markers | ||||
| NSE | 3.25 (1.36–8.18) | 0.0084b | 3.86 (1.35–12.59) | 0.012b |
| ProGRP | 1.67 (0.70–4.17) | 0.25 | 1.53 (0.53–4.70) | 0.43 |
| CYFRA | 0.84 (0.35–2.01) | 0.69 | 0.55 (0.17–1.55) | 0.26 |
| CEA | 2.04 (0.84–5.03) | 0.12 | 4.51 (1.48–15.41) | 0.0082 |
| Stage | 5.37 (2.01–16.06) | 0.0007b | 30.01 (5.62–557.55) | <0.0001b |
| Therapy | 4.94 (1.84–14.80) | 0.0013b | 15.73 (4.02–104.42) | <0.0001b |
| P-SUVmax | 1.00 (0.41–2.39) | 1 | 0.98 (0.36–2.69) | 0.97 |
| H-SUVmax | 1.04 (0.43–2.48) | 0.930 | 1.15 (0.42–3.15) | 0.78 |
| WB-MTV | 3.93 (1.62–10.21) | 0.0024b | 5.31 (1.78–19.44) | 0.0024b |
| WB-TLG | 3.11 (1.29–7.85) | 0.011b | 5.18 (1.73–19.00) | 0.0028b |
| Peripheral type (n = 41) | ||||
| Age | 1.74 (0.86–3.53) | 0.12 | 1.54 (0.68–3.51) | 0.2 |
| Gender (M : F) | 2.29 (0.87–7.92) | 0.097 | 2.89 (0.96–12.38) | 0.061 |
| Smoking index | 1.10 (0.54–2.22) | 0.79 | 1.43 (0.62–3.31) | 0.4 |
| ECOG PS | 1.77 (0.52–4.60) | 0.32 | 1.44 (0.34–4.25) | 0.57 |
| Serum LDH | 1.24 (0.62–2.49) | 0.55 | 1.62 (0.72–3.88) | 0.25 |
| Tumour markers | ||||
| NSE | 2.65 (1.26–5.78) | 0.01b | 3.98 (1.57–11.48) | 0.0031b |
| ProGRP | 1.28 (0.64–2.59) | 0.49 | 1.12 (0.50–2.60) | 0.79 |
| CYFRA | 1.15 (0.58–2.30) | 0.68 | 0.86 (0.37–1.94) | 0.72 |
| CEA | 1.16 (0.57–2.37) | 0.68 | 1.37 (0.61–3.21) | 0.45 |
| Stage | 3.54 (1.66–7.72) | 0.0012b | 6.27 (2.49–17.95) | <0.0001b |
| Therapy | 1.99 (0.95–4.56) | 0.069 | 1.85 (0.76–5.16) | 0.18 |
| P-SUVmax | 1.65 (0.82–3.36) | 0.16 | 1.86 (0.82–4.39) | 0.14 |
| H-SUVmax | 1.82 (0.91–3.73) | 0.090 | 2.27 (0.99–5.65) | 0.052 |
| WB-MTV | 5.21 (2.35–12.51) | <0.0001b | 8.16 (2.95–28.98) | <0.0001b |
| WB-TLG | 4.98 (2.23–11.98) | <0.0001b | 8.02 (2.89–28.53) | <0.0001b |
CEA, carcinoembryonic antigen; CI, confidence interval; CYFRA, cytokeratin 19 fragment; ECOG, Eastern Cooperative Oncology Group; F, female; H-SUVmax, maximum standardized uptake value of the highest lesion of the disease; LDH, lactate dehydrogenase; M, male; NSE, neuron-specific enolase; ProGRP, pro-gastrin-releasing peptide; PS, performance status; P-SUVmax, maximum standardized uptake value of the primary tumour lesion; WB-MTV, whole-body metabolic tumour volume; WB-TLG, whole-body total lesion glycolysis.
a
p < 0.05.
b
p < 0.02.